Haplo-insufficiency of BRCA1 in sporadic breast cancer

Cancer Research

Volumn 63, Issue 16, 2003, Pages 4978-4983

  Staff, Synnöve ^a   Isola, Jorma ^a,b   Tanner, Minna ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; MESSENGER RNA; ONCOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INHIBITION; CORRELATION ANALYSIS; DNA METHYLATION; FINLAND; GENE DELETION; GENE EXPRESSION; HAPLOINSUFFICIENCY; HAPLOTYPE; HUMAN; HUMAN TISSUE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; DNA METHYLATION; FEMALE; GENES, BRCA1; HUMANS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0042941431     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bodgen, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A., and Skolnick. M. H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI. Science (Wash. DC) 266: 66-71, 1994.
2. Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108: 171-182, 2002.
3. Neuhausen, S. L., and Marshall, C. J. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res., 54: 6069-6072, 1994.
4. Esteller, M., Fraga, M. F., Guo, M., Garcia-Foncillas, J., Hedenfalk, I., Godwin, A. K., Trojan, J., Vaurs-Barriere, C., Bignon, Y. J., Ramus, S., Benitez, J., Caldes, T., Akiyama, Y., Yuasa, Y., Launonen, V., Canal, M. J., Rodriguez, R., Capella, G., Peinado, M. A., Borg, A., Aaltonen, L. A., Ponder, B. A., Baylin, S. B., and Herman, J. G. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet., 10: 3001-3007, 2001.
5. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weaver-Feldhaus, J., Ding, W., Gholami, Z., Söderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., Iglehart, J. D., Marks, J., Ballinger, D. G., Barrett, J. C., Skolnick, M. H., Kamb, A., and Wiseman, R. BRCA1 mutations in primary breast and ovarian carcinomas. Science (Wash. DC) 266: 120-122, 1994.
6. Beckmann, M. W., Picard, F., An, H., X., van Royen, C. R. C., Dominik. S. I., Mosny, D. S., Schnürch, H. G., Bender, H. G., and Niederacher, D. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br. J. Cancer, 73: 1220-1226, 1996.
7. Rio, P. G., Pemin, D., Bay, J. O., Albuisson, E., Kwiatkowski, F., De Latour, M., Bernard-Gallon, D. J., and Bignon, Y. J. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma. Int. J. Oncol., 13: 849-853, 1998.
8. Sorlie, T., Andersen, T. I., Bukholm, I., and Borresen-Dale, A. L. Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases. Breast Cancer Res. Treat., 48: 259-264, 1998.
9. Gonzalez, R., Silva, J. M., Dominguez, G., Garcia, J. M., Martinez, G., Vargas, J., Provencio, M., Espana, P., and Bonilla, F. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. Br. J. Cancer, 81: 503-509, 1999.
10. Rio, P. G., Maurizis, J. C., Peffault de Latour, M., Bignon, Y. J., and Bemard-Gallon, D. J. Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCAI gene. Int. J. Cancer. 80: 823-826, 1999.
11. Katsama, A., Sourvinos, G., Zachos; G., and Spandidos, D. A. Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. Cancer Lett., 150: 165-170, 2000.
12. Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L., and Holt, J. T, Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet., 9: 444-450. 1995.
13. Magdinier, F., Ribieras. S., Lenoir. G. M., Frappart, L., and Dante, R. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation pattems patterns of the putative promoter region. Oncogene, 17: 3169-3176. 1998.
14. Sourvinos, G., and Spandidos. D. A. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem. Biophys. Res. Commun., 245: 75-80, 1998.
15. Wilson, C. A., Ramos, L., Villasenor, M. R., Anders. K. H., Press, M. F., Clarke, K., Karlan, B., Chen, J. J., Scully, R., Livingston, D., Zuch, R. H., Kanter, M. H., Cohen, S., Calzone, F. J., and Slamon, D. J. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat. Genet., 21: 236-240, 1999.
16. Rice, J. C., Massey-Brown, K. S., and Futscher. B. W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene. 17: 1807-1812, 1998.
17. Catteau, A., Harris, W. H., Xu, C. F., and Solomon, E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 18: 1957-1965. 1999.
18. Esteller, M., Silva, J. M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Prat, J., Harkes, I, C., Repasky, E. A., Gabrielson, E., Schutte, M., Baylin, S. B., and Herman, J. G. Promoter hypermethylation and BRCAI inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. (Bethesda), 92: 564-569, 2000.
19. Rice, J. C., Ozcelik, H., Maxeiner, P., Andrulis, I., and Futscher, B. W. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis (Lond.) 21: 1761-1765, 2000.
20. Welcsh, P. L., and King, M. C. BRCAI and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet., 10: 705-713, 2001.
21. Kemkemer, R., Schrank, S., Vogel, W., Gruler, H., and Kaufmann, D. Increased noise as an effect of haploinsufficiency of the tumor-suppressor gene neurofibromatosis type I in vitro. Proc. Natl. Acad. Sci. USA. 99: 13783-13788. 2002.
22. Yan, H., Dobbie, Z., Gruber, S. B., Markowitz, S., Romans, K., Giardiello, F. M., Kinzler, K., W., and Vogelstein, B. Small changes in expression affect predisposition to tumorigenesis. Nat. Genet., 30: 25-26. 2002.
23. Wilson, C. A., Payton. M. N., Elliott, G. S., Buaas, F. W., Cajulis, E. E., Grosshans, D., Ramos. L., Reese, D. M., Slamon, D. J., and Calzone, F. J. Differential subcellular localization, expression and biological toxicity of BRCAI and the splice variant BRCA1-delta1 1b Oncogene, 14: 1-16, 1997.
24. Syrjakoski, K., Vahteristo, P., Eerola, H., Tamminen, A., Kivinummi, K., Sarantaus, L., Holli, K., Blomqvist, C., Kallioniemi, O. P., Kainu, T., and Nevanlinna, H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J. Natl. Cancer Inst. (Bethesda), 92: 1529-1531, 2000.
25. Johannsson, O. T., Staff, S., Vallon-Christersson, J., Kytöla, S., Gudjonsson, T., Rennstam, K., Hedenfalk, I. A., Adeyinka, A., Kjellén, E., Wennerberg, J., Baldetorp, B., Petersen, O. W., Olsson, H., Oredsson, S., Isola, J., and Borg. Å. Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. Lab. Investig., 83: 387-396, 2003.
26. Staff, S., Nupponen, N. N., Borg, A., Isola, J. J., and Tanner, M. M. Multiple copies of mutant BRCAI and BRCA2 alleles in breast tumors from germ-line mutation carriers. Genes Chromosomes Cancer. 28: 432-442, 2000.
27. Tanner, M., Jarvinen, P., and Isola, J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res., 61: 5345-5348, 2001.
28. Tanner, M. M., Karhu, R. A., Nupponen, N. N., Borg, A., Baldetorp, B., Pejovic, T., Femo, M., Killander. D., and Isola. J. J. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am. J. Pathol., 153: 191-199, 1998.
29. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826. 1996.
30. Chen, Y., Farmer, A. A., Chen, C. F., Jones, D. C., Chen, P. L., and Lee, W. H. BRCAI is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res., 56: 3168-3172, 1996.
31. Hwang, A., Maity, A., McKenna, W. G., and Muschel, R. J. Cell cycle-dependent regulation of the cyclin BI promoter. J. Biol. Chem., 270: 28419-28424, 1995.
32. Wittwer, C. T., Ririe, K. M., Andrew, R. V., David, D. A., Gundry, R. A., and Balis, U. J. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques, 22: 176-181, 1997.
33. Ozcelik, H., To, M. D., Couture, J., Bull, S. B., and Andrulis, I. L. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int. J. Cancer. 77: 1-6, 1998.
34. Yoshikawa, K., Honda, K., Inamoto, T., Shinohara, H., Yamauchi, A., Suga, K., Okuyama, T., Shimada, T., Kodama, H., Noguchi, S., Gazdar, A. F., Yamaoka, Y., and Takahashi, R. Reduction of BRCAI protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin. Cancer Res., 5: 1249-1261, 1999.,
35. Rennstam, K., Baldetorp, B., Kytola, S., Tanner, M., and Isola, J. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res., 61: 1214-1219, 2001.
36. Bernard-Gallon, D. J., De Latour, M. P., Rio, P. G., Penault-Llorca, F. M., Favy, D. A., Hizel, C., Chassagne, J., and Bignon, Y. J. Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene. Int. J. Oncol., 14: 653-661, 1999.
37. Wilson, C. A., Payton, M. N., Pekar, S. K., Zhang, K., Pacifici, R. E., Gudas, J. L., Thukral, S., Calzone, F. J., Reese, D. M., and Slamon, D. I. BRCA1 protein products: antibody specificity. Nat, Genet., 13: 264-265, 1996.
38. Huber, L. J., Yang, T, W., Sarkisian, C. J., Master, S. R., Deng, C. X., and Chodosh, L. A. Impaired DNA damage response in cells expressing an exon 11-deleted murine Brcal variant that localizes to nuclear foci. Mol. Cell. Biol., 21: 4005-4015, 2001.
39. Fabbro, M., Rodriguez, J. A., Baer, R., and Henderson, B. R. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCAI nuclear export. J. Biol. Chem., 277: 21315-21324, 2002.